AIROS Medical Extends Device Warranty, Setting New Industry Standard

AUDUBON, PA – January 14, 2026 – AIROS Medical, a specialized manufacturer of compression therapy technologies, has announced a significant extension of its product warranty, a move that signals deep confidence in its device durability and provides substantial new assurances to patients managing chronic lymphatic and venous disorders.

Effective for all devices sold after January 1, 2026, the company’s AIROS 6P and AIROS 8P sequential compression devices will now be covered by a five-year warranty, a considerable increase from the previous three-year period. This decision is poised to have a ripple effect across the medical device industry, directly impacting patient costs, provider confidence, and competitive dynamics.

Raising the Bar in a Competitive Market

AIROS Medical's decision to offer a five-year warranty is more than a simple policy update; it represents a direct challenge to the established norms within the pneumatic compression device market. A review of major competitors reveals that this new warranty period is substantially longer than what is currently offered by other key players. For instance, industry leader Tactile Medical provides a one-to-two-year limited warranty on its controllers and garments. Another prominent manufacturer, Bio Compression Systems, offers a three-year warranty for its pump models, which it had previously promoted as the longest in the industry. AIROS Medical has now surpassed that benchmark by a full two years.

This strategic move positions the company, founded in 2016, as a leader in product reliability. In a market projected to grow from approximately $765 million in 2024 to nearly $1.4 billion by 2033, differentiation is critical. By anchoring its brand to durability and long-term support, AIROS is making a calculated play to capture market share and build a reputation for quality that resonates with both healthcare providers and the patients who rely on these devices daily.

Easing the Financial Burden of Chronic Care

For individuals living with lymphedema, a chronic and often progressive condition characterized by painful swelling, the financial burden of treatment can be immense. Studies show the average annual cost of managing lymphedema can exceed $6,000 per patient. The pneumatic compression pumps themselves represent a major investment, with costs potentially ranging from $8,000 to over $21,000. While often covered by insurance, out-of-pocket expenses, deductibles, and the potential cost of out-of-warranty repairs or replacements can be a significant source of financial stress.

An extended five-year warranty directly addresses this concern, offering patients crucial peace of mind and financial protection. By guaranteeing the device's function for a longer period, the policy ensures continuity of care, which is vital for managing symptoms and preventing costly complications like recurrent infections or hospitalizations. This assurance also benefits the Durable Medical Equipment (DME) providers who supply and service these devices. A longer warranty reduces their administrative workload and costs associated with managing repairs and replacements, allowing them to provide more efficient and reliable service to patients.

The Business of Trust and Quality

According to the company, the decision to extend the warranty was not a gamble but a data-driven conclusion based on years of performance tracking. Darren Behuniak, Chief Operating Officer at AIROS Medical, explained the rationale in the company's official announcement.

"Our team at AIROS Medical incorporates a vigorous quality standard with regards to all aspects of our business, including our device line's long-term reliability," Behuniak stated. "Data shows that our internal key performance indicators related to device durability have been met or exceeded since our company's inception, giving us the confidence to provide this expanded, industry-leading warranty. This decision reflects our continued commitment to supporting the lymphedema patients, healthcare professionals treating lymphatic and venous disorders, and our trusted durable medical equipment customers who all rely on AIROS every day."

This confidence is backed by a history of regulatory approvals. The company has secured multiple U.S. Food and Drug Administration (FDA) 510(k) clearances for its devices and garments since 2018, including for its newest AIROS 8P system with advanced peristaltic mode functionality. While the specific internal performance metrics remain proprietary, taking such a public stance on product longevity signals a deep-seated belief in the company’s engineering and manufacturing processes. This move effectively transforms a product feature—durability—into a core tenet of the company's brand identity.

A Ripple Effect on Industry Standards

The impact of AIROS Medical's announcement is expected to extend beyond its own customer base. By establishing a new, higher benchmark for device warranties, the company is placing implicit pressure on its competitors to re-evaluate their own offerings. Industry analysts anticipate that other manufacturers may be compelled to either match the five-year warranty period or find new ways to differentiate their products, perhaps by emphasizing unique garment designs or advanced therapeutic features.

This competitive pressure could ultimately benefit all consumers in the lymphedema and venous disorder space. A market-wide shift toward longer warranties would force manufacturers to invest more heavily in quality control and durable design, leading to more reliable products across the board. Furthermore, it shifts the conversation from the initial purchase price to the total cost of ownership over the device's lifespan—a metric increasingly important to both patients and healthcare systems focused on long-term value. As the market for lymphedema treatment continues to evolve with legislative changes like the Lymphedema Treatment Act, a proven commitment to product quality and patient support may become an even more critical factor for success.